As reported in GSK, the FDA has just granted priority review to Nucala (mepolizumab), a targeted biological treatment to help patients with hypereosinophilic syndrome (HES). If the medication is accepted,…
According to a drug filing and press release from Pharmaceutical Business Review, the FDA granted a priority review to GlaxoSmithKline for their humanized monoclonal antibody therapy, Nucala (mepolizumab). Currently,…
According to a press release from global pharmaceuticals titan GlaxoSmithKline, the US Food and Drug Administration (FDA) recently expanded approval of the Company's eosinophilic asthma treatment Nucala (generic name mepolizumab)…
Hypereosinophilic Syndrome Hypereosinophilic syndrome (HES) is a rare disease which causes high levels of white blood cells in the body. These cells are called eosinophils, and they're essential for proper…
Hypereosinophilic syndrome Hypereosinophilic syndrome (HES) refers to a group of rare conditions characterized by high levels of eosinophils which result in organ damage. These eosinophils often affect the lungs, heart, skin,…
No one knows how difficult living with hypereosinophilic syndrome (HES) is unless you walk in the shoes of those who have it, treat it, or have a loved one who…
Not only does Pamela Looney have hypereosinophilic syndrome (HES), she also has asthma and has suffered from a tumor. At only 15, the sudden development of this tumor severely affected…
© Copyright Patient Worthy
